You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 209401

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 209401 describes VYXEOS, which is a drug marketed by Celator Pharms and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug. Additional details are available on the VYXEOS profile page.

The generic ingredient in VYXEOS is cytarabine; daunorubicin. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cytarabine; daunorubicin profile page.
Summary for 209401
Applicant:Celator Pharms
Ingredient:cytarabine; daunorubicin
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 209401
Generic Entry Date for 209401*:
Constraining patent/regulatory exclusivity:
FDA exclusivity

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 209401
Suppliers and Packaging for NDA: 209401
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401 NDA Jazz Pharmaceuticals, Inc. 68727-745 68727-745-01 20 mL in 1 VIAL (68727-745-01)
VYXEOS cytarabine; daunorubicin POWDER;INTRAVENOUS 209401 NDA Jazz Pharmaceuticals, Inc. 68727-745 68727-745-02 40 mL in 1 CARTON (68727-745-02)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrength100MG;44MG
Approval Date:Aug 3, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 3, 2024
Regulatory Exclusivity Use:
Patent:  Get Started for $10Patent Expiration:Sep 29, 2034Product Flag?YSubstance Flag?Delist Request?
Patent:  Get Started for $10Patent Expiration:Oct 15, 2032Product Flag?YSubstance Flag?Delist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.